Singapore markets closed
Straits Times Index
3,290.70 +24.75 (+0.76%) Nikkei
38,229.11 +155.13 (+0.41%) Hang Seng
18,963.68 +425.87 (+2.30%) FTSE 100
8,445.47 +64.12 (+0.77%) Bitcoin USD
62,925.87 +1,454.72 (+2.37%) CMC Crypto 200
1,306.53 -51.48 (-3.79%)
Aridis Pharmaceuticals, Inc. (ARDS)
Other OTC - Other OTC Delayed price. Currency in USD
Add to watchlist
At close: 03:56PM EDT
| Previous close | 0.0565 |
| Open | 0.0580 |
| Bid | 0.0000 x 1000 |
| Ask | 0.0000 x 1800 |
| Day's range | 0.0571 - 0.0590 |
| 52-week range | 0.0500 - 0.5395 |
| Volume | |
| Avg. volume | 67,779 |
| Market cap | 2.63M |
| Beta (5Y monthly) | 1.08 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Zacks
Aridis (ARDS) Up on Receiving FDA's QIDP Designation for AR-301
Aridis (ARDS) achieves a milestone as the FDA granted the Qualified Infectious Disease Product designation for AR-301.
- Zacks
Aridis (ARDS) Up on Regulatory Update for Pneumonia Drug
Aridis (ARDS) announces that its AR-301 clinical program is eligible for availing the FDA's special pathway for satisfying the unmet medical need of a predefined limited population.
- Zacks
Aridis (ARDS) Up After FDA Nod for Pneumonia Drug Study Design
Aridis (ARDS) stock jumps 115% after the company reports reaching an agreement with the FDA on its proposed study on AR-301 as an adjunctive treatment for hospital-acquired pneumonia.
© 2024 Yahoo. All rights reserved.